Hearing Disorders – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hearing Disorders – Drugs In Development, 2024 report and make more profitable business decisions.
Hearing loss is an extremely common medical condition, ranging from neonates to the elderly, progressing in incidence and severity with age; about one-third of older adults have hearing loss. Diagnosis and management require an interprofessional team that includes the general practitioner, otolaryngologist, speech therapist, audiologist, and social worker. To correctly address hearing loss, understanding the nature of hearing loss and the equipment that is needed to improve auditory reception is crucial. In terms of children’s hearing loss, pediatricians need to be integrated into their care to ensure normal hearing and language development of the child. Hearing loss is a common problem caused by loud noise, aging, disease, and genetic variations. The three basic categories of hearing loss are sensorineural hearing loss, conductive hearing loss, and mixed hearing loss. Conductive involves the outer or middle ear, sensorineural involves the inner ear, and mixed involves both. Symptoms of hearing loss may include muffling of speech and other sounds, trouble hearing letters of the alphabet that aren’t vowels, and often asking others to speak more slowly, clearly, and loudly.
The Hearing Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hearing Disorders and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hearing Disorders | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 87 molecules, with 81 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hearing Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hearing Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hearing Disorders treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
13therapeutics IncAcousia Therapeutics GmbH
Adare Pharma Solutions
Affichem SA
Akouos Inc
Anida Pharma Inc
Antion Biosciences SA
Arbormed Co Ltd
AudioCure Pharma GmbH
Audion Therapeutics BV
Autifony Therapeutics Ltd
Bodor Laboratories Inc
Boehringer Ingelheim International GmbH
Calliditas Therapeutics France SAS
Chaperone Therapeutics Inc
CILcare SAS
Daewoong Pharmaceutical Co Ltd
Dendrogenix SA
Gateway Biotechnology Inc
Hoba Therapeutics ApS
HuidaGene Therapeutics Co Ltd
IMD Farm Co Ltd
ImmunityBio Inc
iN Therapeutics Inc
Jacaranda Biosciences Inc
Knopp Biosciences LLC
Kyungpook National University
Lineage Cell Therapeutics Inc
Massachusetts Institute of Technology
Mogrify Ltd
Myrtelle Inc
NeurAegis Inc
Nobelpharma Co Ltd
Novartis AG
O-Ray Pharma Inc
Oblato Inc
Otologic Pharmaceutics Inc
Otonomy Inc
Paean Biotechnology Inc
Pasteur Institute
Perceive Biotherapeutics Inc
Prime Medicine Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
ReNeuron Group Plc
Rescue Hearing Inc
Rinri Therapeutics Ltd
Rophibio Inc
Sensorion SA
Sinfonia Biotherapeutics Inc
SIU School of Medicine
Sound Pharmaceuticals Inc
Spiral Therapeutics Inc
St. Jude Children’s Research Hospital Inc
Surrozen Inc
Swedish Orphan Biovitrum AB
Ting Therapeutics LLC
Yonsei University
Zebra Biologics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hearing Disorders reports